Quantcast

Latest Rivastigmine Stories

2014-07-02 23:03:21

MarketReportsOnline.com adds "Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs Analysis" report to its research store. Dallas, Texas (PRWEB) July 02, 2014 Alzheimer’s is a complex disease and there is no single “magic bullet” available in the market to prevent or cure it. Though many marketed drugs have been approved for Alzheimer’s disease, it still remains a significant area of unmet medical need. Clinical success has...

2014-06-19 08:29:24

DUBLIN, June 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of Delaware has found certain claims of United States Patent Nos. 6,335,031 and 6,316,023 valid and infringed by Actavis' generic version of Novartis' Exelon(®) Patch (rivastigmine transdermal system). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal. Exelon(®) Patch is a prescription medicine...

2013-11-21 23:19:32

Reportbuyer.com just published a new market research report: PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022. London (PRWEB) November 21, 2013 PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so...

2013-10-29 23:21:16

Reportbuyer.com just published a new market research report: PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022. London (PRWEB) October 29, 2013 PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so...

2013-10-24 23:18:56

Reportbuyer.com just published a new market research report: PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) October 24, 2013 PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains...

2013-10-24 23:04:24

Reportbuyer.com just published a new market research report: PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022. London (PRWEB) October 24, 2013 PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so...

2013-10-21 23:20:54

Reportbuyer.com just published a new market research report: PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022. London (PRWEB) October 21, 2013 PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains...

Cognitive Enhancers Not Effect Against Cognitive Impairment
2013-09-17 08:41:15

redOrbit Staff & Wire Reports - Your Universe Online Memory and concentration-improving drugs do not improve cognition or brain function, and may actually cause adverse health effects in people with mild cognitive impairment, according to research in Monday’s edition of the Canadian Medical Association Journal. These medications, which are known as cognitive enhancers, were found to be ineffective in treating patients suffering from mild cognitive impairment, a condition marked by...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.